Evaluation of combined treatment with Er:YAG laser and long‐pulsed Nd:YAG laser for the treatment of recalcitrant warts: A prospective randomized controlled trial
Background Viral warts are common infectious skin disease induced by human papillomavirus (HPV). Lasers have been used for warts treatment in recent years with variable success rates. Objective This study aimed to prospectively evaluate combined treatment with Er:YAG laser and long‐pulsed Nd:YAG las...
Saved in:
Published in | Journal of the European Academy of Dermatology and Venereology Vol. 37; no. 12; pp. 2569 - 2574 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
England
01.12.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Background
Viral warts are common infectious skin disease induced by human papillomavirus (HPV). Lasers have been used for warts treatment in recent years with variable success rates.
Objective
This study aimed to prospectively evaluate combined treatment with Er:YAG laser and long‐pulsed Nd:YAG laser compared to Er:YAG laser for the treatment of recalcitrant warts after one session.
Materials and Methods
This study included 240 lesions from 24 patients. All the lesions were diagnosed clinically as recalcitrant warts after failure of topical treatment and cryotherapy. About 120 lesions underwent a combined therapy of Er:YAG and long‐pulsed (LP) Nd:YAG lasers, and the remaining 120 lesions underwent Er:YAG laser therapy only. The clearance rate was evaluated 5 weeks after and classified by three‐graded evaluation: complete response, partial response and poor response.
Results
The clearance rate in the combined Er:YAG + LP Nd:YAG lasers group was, statistically significant, higher than that of the Er:YAG laser group (p = 0.008). The complete response rate was 48% (58 of 120 warts) for the Er:YAG +LP Nd:YAG lasers group and only 29% (35 of 120 warts) for the Er:YAG laser group.
Conclusion
The combination of Er:YAG and long‐pulsed Nd:YAG lasers is more effective than Er:YAG laser alone in treating recalcitrant warts after single session. |
---|---|
Bibliography: | ClinicalTrials.gov Identifier: NCT05768893. Trial registration ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
ISSN: | 0926-9959 1468-3083 |
DOI: | 10.1111/jdv.19388 |